Improved survival of HIV-1-infected patients with progressive Multifocal Leukoencephalopathy receiving early 5-drug combination Antiretroviral therapy

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Gasnault, Jacques ^a,b   Costagliola, Dominique ^b,c,d   Hendel Chavez, Houria ^a,b   Dulioust, Anne ^a   Pakianather, Sophie ^b   Mazet, Anne Aurélie ^a   de Goer de Herve, Marie Ghislaine ^b   Lancar, Rémi ^b   Lascaux, Anne Sophie ^e   Porte, Lydie ^f   Delfraissy, Jean François ^a,b,g   Taoufik, Yassine ^a,b,g  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f CHU PURPAN   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LOPINAVIR; RITONAVIR; TENOFOVIR; VIRUS DNA; VIRUS RNA; ANTIRETROVIRUS AGENT; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIVIRAL THERAPY; ARTICLE; CALCIUM BLOOD LEVEL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID LEVEL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOPENIA; DNA DETERMINATION; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EARLY INTERVENTION; EPILEPSY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LUNG EMBOLISM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SIDE EFFECT; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; UROLITHIASIS; VIRUS REPLICATION; CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JC VIRUS; MIDDLE AGED; MORTALITY; PATHOGENICITY; POLYMERASE CHAIN REACTION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; JC POLYOMAVIRUS;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION;

EID: 79959809679     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020967     Document Type: Article

References (36)

1. Berger JR, Chauhan A, Galey D, Nath A, (2001) Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neurovirol 7: 329-338.
2. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, et al. (2004) Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55: 320-328.
3. Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, et al. (2009) Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 199: 77-83.
4. Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, et al. (2008) Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 9: 246-256.
5. Mocroft A, Sterne JA, Egger M, May M, Grabar S, et al. (2009) Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 48: 1138-1151.
6. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, et al. (2004) A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127: 1970-1978.
7. Day CL, Walker BD, (2003) Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med 198: 1773-1777.
8. Gasnault J, Kahraman M, de Goer de Herve MG, Durali D, Delfraissy JF, et al. (2003) Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 17: 1443-1449.
9. Gasnault J, Taoufik Y, (2006) [New trends in progressive multifocal leukoencephalopathy]. Rev Neurol (Paris) 162: 43-56.
10. Cinque P, Casari S, Bertelli D, (1998) Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy. N Engl J Med 339: 848-849.
11. Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, et al. (1999) HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52: 623-625.
12. Gasnault J, Taoufik Y, Goujard C, Kousignian P, Abbed K, et al. (1999) Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 5: 421-429.
13. De Luca A, Giancola ML, Ammassari A, Grisetti S, Paglia MG, et al. (2000) The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 182: 1077-1083.
14. Antinori A, Cingolani A, Lorenzini P, Giancola ML, Uccella I, et al. (2003) Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 9 (Suppl 1): 47-53.
15. De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, et al. (2008) Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 22: 1759-1767.
16. Molto J, Ruiz L, Valle M, Martinez-Picado J, Bonjoch A, et al. (2006) Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. Antivir Ther 11: 47-51.
17. Raffi F, Katlama C, Saag M, Wilkinson M, Chung J, et al. (2006) Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 42: 870-877.
18. Reynes J, Arasteh K, Clotet B, Cohen C, Cooper DA, et al. (2007) TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 21: 533-543.
19. Cinque P, Pierotti C, Vigano MG, Bestetti A, Fausti C, et al. (2001) The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 7: 358-363.
20. Cinque P, Koralnik IJ, Clifford DB, (2003) The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 9 (Suppl 1): 88-92.
21. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J, (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19: 604-607.
22. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, et al. (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20: 864-870.
23. Herman J, Van Ranst M, Snoeck R, Beuselinck K, Lerut E, et al. (2004) Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr Transplant 8: 485-492.
24. Letendre SL, Ellis RJ, Ances BM, McCutchan JA, (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18 (2): 45-55.
25. Falco V, Olmo M, del Saz SV, Guelar A, Santos JR, et al. (2008) Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 49: 26-31.
26. Tan K, Roda R, Ostrow L, McArthur J, Nath A, (2009) PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72: 1458-1464.
27. Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, et al. (2005) Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 109: 449-455.
28. Taoufik Y, Gasnault J, Karaterki A, Pierre Ferey M, Marchadier E, et al. (1998) Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 178: 1816-1820.
29. Tada H, Rappaport J, Lashgari M, Amini S, Wong-Staal F, et al. (1990) Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc Natl Acad Sci U S A 87: 3479-3483.
30. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A, (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
31. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, et al. (2003) HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 198: 1909-1922.
32. de Goer de Herve MG, Cariou A, Simonetta F, Taoufik Y, (2008) Heterospecific CD4 help to rescue CD8 T cell killers. J Immunol 181: 5974-5980.
33. Williams MA, Bevan MJ, (2007) Effector and memory CTL differentiation. Annu Rev Immunol 25: 171-192.
34. Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, et al. (2002) Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 168: 499-504.
35. Lima MA, Marzocchetti A, Autissier P, Tompkins T, Chen Y, et al. (2007) Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol 81: 3361-3368.
36. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, et al. (2009) Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 119: 997-1007.